ROCA Ovarian Screening Blood Test Class Action Investigation
McCune Wright Arevalo, LLP is investigating a class action lawsuit on behalf of individuals who purchased the Risk of Ovarian Cancer Algorithm (ROCA) blood test. Abcodia manufactures the ROCA blood test, which is marketed to detect the likelihood of ovarian cancer in women ages 50-85. Abcodia’s marketing claims promise that the ROCA test detects twice the number of cancers than the CA-125 test. The FDA recently stated that “there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a high number of inaccurate results.” According to the FDA, the current available data does not support the ROCA marketing claims. The FDA stated “Abcodia Incorporated began marketing the Risk of Ovarian Cancer Algorithm (ROCA) test in the United States, with claims that the ROCA test can screen for and detect ovarian cancer before symptoms appear and increase the chance for survival. Yet, available data do not support its claims.” If you purchased a ROCA test, please contact McCune Wright Arevalo, LLP today.